Sermorelin Compound Reference
Published · Last updated · Publisher: ENOS Labs USA
What is Sermorelin?
Sermorelin is the 29 residue amino terminal fragment of growth hormone releasing hormone, the shortest sequence with full activity. It was once FDA approved as Geref for diagnosing and treating growth hormone deficiency in children, but that product was discontinued in the United States. Research grade sermorelin is not an approved drug.
- Synonyms
- GRF(1-29)NH2; Geref (former drug product)
- Classification
- Synthetic peptide equal to the first 29 residues of GHRH
What is Sermorelin?
Sermorelin reproduces GHRH(1-29) with a C terminal amide. It is the parent sequence for later analogs such as CJC-1295.
Research context
Clinical literature covers pediatric growth hormone deficiency diagnosis and treatment, and later discussion of adult growth hormone insufficiency.
Mechanisms being investigated
- GHRH receptor activation in the pituitary, preserving feedback regulation of growth hormone.
Research status
Approval status: Previously approved, discontinued. Highest evidence tier in the cited literature: clinical trials.
Previously FDA approved (Geref); the product was discontinued and is no longer marketed. No current approved research use.
Established findings
- Its activity at the GHRH receptor and historical approved diagnostic use.
Preliminary or experimental findings
- Adult uses discussed in reviews, which were not established by trials leading to approval.
Chemical reference information
| Molecular formula | C149H246N44O42S |
|---|---|
| Molecular weight | 3357.9 g/mol |
| CAS number | 86168-78-7 |
| PubChem CID | 16132413 |
Values taken from the PubChem record.
Testing considerations
- Methionine at position 27 is prone to oxidation; check the impurity profile for oxidized forms.
General methods are explained in purity versus identity testing.
What is still unknown
- Current clinical relevance given discontinuation.
Related resources
ENOS catalog listing: Sermorelin 10MG
Research use limitations
This page summarizes published research and regulatory status. It is not medical advice and does not describe any use in people. Material supplied by ENOS Labs USA is for in-vitro laboratory research only and is not a drug product, even where a related drug has been approved.
To continue, see recovery and performance research, how to read a certificate of analysis, why purity and identity are separate tests, the compound directory and the peptide testing glossary.
References
Each source below was opened and checked against its PubMed, ClinicalTrials.gov or PubChem record. Links open in a new tab.
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency (PMID 18031173)BioDrugs, 1999 · PubMed
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? (PMID 18046908)Clinical Interventions in Aging, 2006 · PubMed
- Sermorelin compound record (PubChem CID 16132413)PubChem · NIH National Library of Medicine
These products are sold strictly for in-vitro laboratory research and are not intended for human consumption, diagnosis, treatment, or any therapeutic use. Purchaser must be 18 years of age or older and confirms they are a qualified researcher.